NewLink Genetics Announces Final Results from Phase 2 Studies of Indoximod in Advanced Melanoma and Metastatic Pancreatic Cancer to be Presented at ASCO 2018

World News: . []

AMES, Iowa, May 16, 2018 (GLOBE NEWSWIRE) -- (NASDAQ:NLNK) today announced that abstracts from two Phase 2 studies of indoximod, used in combination with other agents, are now available on the website of the . Presentation sessions and times are noted below.  Additional data will be presented at ASCO.   

Indoximod is an investigational, orally available small molecule targeting the IDO pathway. The IDO pathway is a key immuno-oncology target involved in regulating the tumor microenvironment and immune escape. Indoximod is being evaluated in combination with treatment regimens including chemotherapy, radiation, checkpoint blockade and cancer vaccines across multiple indications such as AML, DIPG and melanoma.

NewLink Genetics is a clinical stage biopharmaceutical company focusing on discovering, developing and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer. NewLink Genetics' IDO pathway inhibitors are designed to harness multiple components of the immune system to combat cancer. For more information, please visit  and follow us on Twitter .

Investor Contact:

Lisa MillerDirector of Investor RelationsNewLink Genetics515-598-2555

Media Contact:

Sharon CorreiaVP, Integrated CommunicationsLaVoieHealthScience617-374-8800, ext. 105

More news and information about NewLink Genetics Corporation

Published By:

Globe Newswire: 22:00 GMT Wednesday 16th May 2018

Published: .

Search for other references to "newlink" on SPi News

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
Sector Publishing Intelligence Ltd.
Ground Floor Offices, Little Keep Gate, Barrack Road, Dorchester, Dorset DT1 1AH
Registered in England and Wales number 0751938.
Privacy Policy | Terms and Conditions | Contact Us

Advertising on SPi News: Information For Advertisers